Keywords: cat, dyax, expand, licensing, deal, uk, cambridge

CAT and Dyax expand licensing deal

Article | 29 September 2003

Print This

The UK's Cambridge Antibody Technology and Nasdaq-listed Dyax have amended their licensing deal relating to CAT's patents on therapeutic and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in